First human test of new cancer pill begins
NCT ID NCT06077877
Summary
This early-stage study is testing a new oral drug called GSK4524101, both by itself and combined with an existing cancer drug (niraparib), in adults with advanced solid tumors. The main goals are to find safe dose levels and see if the treatment can shrink tumors. It is for people who have already tried all standard treatments available to them.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
San Francisco, California, 94158, United States
-
GSK Investigational Site
St Louis, Missouri, 63110, United States
-
GSK Investigational Site
Dallas, Texas, 75230, United States
-
GSK Investigational Site
Houston, Texas, 77030, United States
-
GSK Investigational Site
San Antonio, Texas, 78229, United States
-
GSK Investigational Site
Fairfax, Virginia, 22031, United States
-
GSK Investigational Site
Porto Alegre, 90020-090, Brazil
-
GSK Investigational Site
Vitória, 29043-260, Brazil
-
GSK Investigational Site
Edmonton, Alberta, T6G 1Z2, Canada
-
GSK Investigational Site
Toronto, Ontario, M5G 2M9, Canada
-
GSK Investigational Site
Montreal, Quebec, H4A 3J1, Canada
-
GSK Investigational Site
Panama City, Panama
-
GSK Investigational Site
Punta Pacifica Panama City Panama, Panama
Conditions
Explore the condition pages connected to this study.